Supplementary file



Suppl. Fig. 1. Risk of bias, presented with the Cochrane Collaboration's Assessment Tool.



Suppl. Fig. 2. Risk ratio (95%CI) for bDMARDs in terms of fulfilling the ACR50 response criteria compared to placebo, pooled per class (higher is better).



Suppl. Fig. 3. Risk ratio (95%CI) for bDMARDs in terms of fulfilling the ACR70 response criteria compared to placebo, pooled per class (higher is better).



Suppl. Fig. 4. Risk ratio (95%CI) for bDMARDs in terms of fulfilling the ACR20 response criteria compared to placebo, pooled per class, in patients naïve to bDMARDs (higher is better).



Suppl. Fig. 5. Risk ratio (95%CI) for bDMARDs in terms of fulfilling the PASI90 response criteria compared to placebo, pooled per class (higher is better).



Suppl. Fig. 6. Mean HAQ-DI difference (95%CI) for bDMARDs compared to placebo, pooled per class (lower is better).